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Acute inflammation and its resolution are essential processes for tissue protection and
homeostasis. Once thought to be a passive process, the resolution of inflammation is now
shown to involve active biochemical programs that enable inflamed tissues to return to
homeostasis. The mechanisms by which acute inflammation is resolved are of interest,
and research in recent years has uncovered new endogenous anti-inflammatory and pro-
resolving lipid mediators (i.e., lipoxins, resolvins, protectin, and maresin) generated from
polyunsaturated fatty acids (PUFAs).This review presents new insights into the cellular and
molecular mechanisms of inflammatory resolution, especially the roles of eosinophils, and
a series of omega-3 PUFA-derived anti-inflammatory lipid mediators that they generate.
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INTRODUCTION
Inflammation is a defensive response to injury and infec-
tion, but excessive or inappropriate inflammation contributes
to a range of acute and chronic human diseases. Acute local
inflammation in healthy individuals is self-limited and resolves
by means of an active termination program (Gilroy et al.,
2004; Serhan and Savill, 2005). The mechanisms that regu-
late the progression and resolution of inflammation remain of
interest. Lipid mediator metabolomics of self-resolving inflam-
matory exudates recently uncovered a new family of potent
anti-inflammatory and pro-resolving mediators. These include
arachidonic acid (AA)-derived lipoxins, eicosapentaenoic acid
(EPA)-derived E-series resolvins, docosahexaenoic acid (DHA)-
derived D-series resolvins, protectin, and maresin (Bannen-
berg and Serhan, 2010). In inflammatory exudates, lipid medi-
ators change in the course of acute inflammation and res-
olution (Levy et al., 2001; Bannenberg et al., 2005; Blaho
et al., 2009; Yamada et al., 2011). In this review, we provide
an overview of the novel cellular and molecular components
involved in lipid mediator class switching during resolution of
inflammation, especially eosinophils and the lipid mediators that
they generate.
INFLAMMATORY RESPONSE AND THE RESOLUTION OF
INFLAMMATION
Inflammation is a host defense mechanism that is characterized by
the movement of serum proteins and leukocytes from the blood to
the extravascular tissue. The acute inflammatory response is char-
acterized by the initial recruitment of neutrophils, followed by
the recruitment of monocytes that differentiate into macrophages
(Figure 1). Many mediators coordinate the initial events of acute
inflammation. Lipid mediators such as prostaglandins (PGs)
and leukotrienes (LTs), cytokines, and chemokines coordinately
regulate vascular permeability and leukocytes infiltration (Larsen
and Henson, 1983). Once the noxious materials are removed via
phagocytosis, the inflammatory reaction must be resolved to main-
tain homeostasis. The resolution of acute inflammation is an active
process that is controlled by endogenous pro-resolving media-
tors. These factors switch off leukocyte trafficking to the inflamed
site, reverse vasodilation, and vascular permeability, and promote
the clearance of inflammatory cells, exudates, and tissue debris,
thereby leading to the restoration of homeostasis to the inflamed
tissue. AA-derived lipoxin A4 (LXA4) was the first PUFA-derived
mediator found to have anti-inflammatory and/or pro-resolving
activities (Godson et al., 2000; Serhan, 2005). Nanomolar concen-
trations of LXA4 inhibit polymorphonuclear leukocyte (PMN)
entry into inflamed tissues in animal models (Colgan et al., 1993).
LXA4 is synthesized by the actions of both 15-lipoxygenase (15-
LOX) and 5-LOX, and phosphorylation of 5-LOX at S663 was
recently shown to convert the enzyme to a robust 15-LOX, which
can stimulate production of LXA4 in cells which do not express
15-LOX (Gilbert et al., 2012). Also, omega-3 fatty acids EPA and
DHA are precursors of endogenous anti-inflammatory and/or
pro-resolving mediators. Using an unbiased lipidomics approach
and the enzymatic oxygenation of omega-3 fatty acids, Serhan
and collaborators identified families of novel bioactive mediators
derived from EPA and DHA. These include EPA-derived E-series
resolvin (RvE1, E2; Serhan et al., 2000; Arita et al., 2005; Tjona-
hen et al., 2006), DHA-derived D-series resolvin (RvD1-6; Serhan
et al., 2002; Sun et al., 2007; Spite et al., 2009; Chiang et al.,
2012), neuroprotectin/protectin (NPD1/PD1; Hong et al., 2003;
Marcheselli et al., 2003; Serhan et al., 2006), and maresin (MaR1;
Serhan et al., 2009, 2012). These lipid mediators promote reso-
lution via enhanced macrophage clearance of apoptotic PMNs,
chemokines, cytokines, and microbial products (Ariel et al., 2006;
Schwab et al., 2007). In the course of acute inflammation and
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FIGURE 1 | Major processes in acute inflammation and resolution. The
initiation phase of acute inflammation is characterized by the rapid
infiltration of polymorphonuclear neutrophils (PMNs) followed by the
infiltration of monocytes that mature into macrophages, and edema
formation in response to injury. PMNs provide the first line of immune
defense by migrating to sites of injury and neutralizing invading
microorganisms or noxious materials by phagocytosis. In the resolution
phase, PMNs undergo apoptosis and are ingested by macrophages that
emigrate rapidly from the inflamed site to the draining lymph nodes
(DLNs).
FIGURE 2 | Eosinophils are recruited to the inflamed loci and promote
resolution of inflammation by producing anti-inflammatory and
pro-resolving lipid mediators. During the resolution phase of self-resolving
acute peritonitis model, eosinophils are recruited to the inflammatory site,
where they locally produce pro-resolving lipid mediators such as PD1 via
12/15-LOX-initiated biosynthesis. These mediators block PMN infiltration
and/or promote the clearance of phagocytes carrying engulfed zymosan from
the inflammatory site to DLNs.
resolution, changes of cellular composition or cell–cell interac-
tions are accompanied by a switch of lipid mediator profiles
in exudates (Serhan, 1997, 2007). The temporal switch in lipid
mediator class is an active process that they underscore the ability
of inflammatory cells to trigger the self-limited response of acute
inflammation.
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NOVEL ROLES OF EOSINOPHILS IN PROMOTING THE
RESOLUTION OF ACUTE INFLAMMATION
The profile of lipid mediators during inflammation-resolution
was determined with a liquid chromatography-tandem mass
spectrometry (LC-MS/MS)-based lipidomic analysis. In murine
zymosan-induced peritonitis, the maximal levels of 5-LOX prod-
ucts such as leukotriene B4 (LTB4) were observed in the initiation
phase, and subsequently decreased during the resolution. In com-
parison, the levels of 12/15-LOX products such as protectin D1
(PD1) were low at the initiation of inflammation, then grad-
ually increased during the resolution phase. The DHA-derived
lipid mediator PD1 is biosynthesized via a 12/15-LOX-mediated
pathway that converts DHA into a 10,17-dihydroxy-containing
bioactive molecule (Hong et al., 2003; Marcheselli et al., 2003; Ser-
han et al., 2006). PD1 promotes resolution by counter regulating
PMN influx and stimulating macrophage ingestion of apoptotic
PMNs, and increasing phagocyte clearance into DLNs (Schwab
et al., 2007). Therefore, the major cellular components of PD1
biosynthesis in the resolution phase were of interest. Recently we
identified eosinophils as major PD1-producing cells in the resolu-
tion phase of zymosan-induced peritonitis (Yamada et al., 2011).
Eosinophils are multifunctional leukocytes that have been impli-
cated in the pathogenesis of numerous inflammatory processes,
including parasitic infections and allergic diseases. However, the
roles of eosinophils in acute inflammation and resolution are
unclear. To determine the role of eosinophils in the resolution
of inflammation, an anti-IL-5 monoclonal antibody (Corry et al.,
1996) was administered to deplete eosinophils from mice chal-
lenged with zymosan. In vivo depletion of eosinophils resulted in
an increased number of PMNs and a reduced number of phago-
cytes leaving the inflamed peritoneum to the draining lymph
nodes (DLNs), both of which showed a resolution deficit. The
LC-MS/MS-based lipidomic analysis revealed that the amounts
of 12/15-LOX-derived mediators including PD1 were dramati-
cally decreased in eosinophil-depleted mice, whereas the amounts
of COX and 5-LOX derived products did not differ between the
two groups. Adoptive transfer of wild type eosinophils, but not
eosinophils from 12/15-LOX knockout mice, successfully restored
the resolution phenotype. Also, administration of PD1 restored
the resolution phenotype. These results indicate that eosinophils
are recruited to the inflamed loci during the resolution phase,
where they locally produce anti-inflammatory and pro-resolving
lipid mediators such as PD1 via a 12/15-LOX-initiated biosynthetic
route, which contribute to resolution (Figure 2).
Eosinophils are circulating granulocytes that typically mature
in the bone marrow, and can be recruited to sites of immuno-
logical or inflammatory responses. Triggering of eosinophils by
engagement of receptors for cytokines, immunoglobulins, or com-
plement can lead to the secretion of an array of cytokines [IL-2,
IL-4, IL-5, IL-10, IL-12, IL-13, IL-16, IL-18, and transforming
growth factors (TGF-α/β)], chemokines (RANTES and eotaxin-1),
lipid mediators [platelet-activating factor (PAF), and leukotriene
C4 (LTC4)], and cytotoxic granule cationic proteins [major basic
protein (MBP), eosinophil peroxidase (EPO), eosinophil cationic
protein (ECP), and eosinophil-derived neurotoxin (EDN; Gleich
and Adolphson, 1986; Kita, 1996]. These mediators are gener-
ally considered to be involved in the eosinophil-mediated defense
FIGURE 3 | Generation of RvE3, a novel anti-inflammatory lipid
mediator, by eosinophils. RvE3 was identified by unbiased target
lipidomics. While other E-series resolvins such as RvE1 and RvE2 are
biosynthesized by human PMNs via the 5-LOX pathway, RvE3 is generated
by eosinophils via the 12/15-LOX pathway from a common precursor,
18-HEPE. It is likely that hydrogen abstraction from C13 by 12/15-LOX
induced a stereospecific oxygen insertion at C17, leading to the formation of
RvE3. RvE3 displayed a potent anti-inflammatory action by limiting PMN
infiltration in zymosan-induced acute peritonitis.
against parasitic infections. Also, locally accumulated eosinophils
are considered to be involved in the pathogenesis of allergic dis-
eases such as asthma. Recently, eosinophils were shown to promote
alternatively activated macrophages in an IL-4 and IL-13 depen-
dent manner, which in turn improved glucose metabolism (Wu
et al., 2011). Eosinophils in the resolution phase may modulate
macrophage phenotype, and thereby promote resolution of acute
inflammation.
A NOVEL EOSINOPHIL-DERIVED LIPID MEDIATOR WITH
ANTI-INFLAMMATORY PROPERTIES
Omega-3 PUFAs such as EPA and DHA are enriched in
fish oils, and have beneficial effects in many inflammatory
disorders including cardiovascular disease, arthritis, colitis, and
asthma. Omega-3 PUFAs have been proposed to act via sev-
eral mechanisms, such as by preventing conversion of omega-6
PUFA arachidonic acid to pro-inflammatory eicosanoids, and
by being converted to potent anti-inflammatory mediators such
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FIGURE 4 | Proposed mechanisms of eosinophils’ pro-resolving function.
Eosinophils play a role in host defense by releasing cytotoxic granule proteins,
cytokines/chemokines, and mediators. In addition, eosinophils maintain
metabolic homeostasis by promoting alternative macrophage activation in an
IL-4- and IL-13- dependent manner. Thus, it is proposed that eosinophils
promote resolution of inflammation by blocking PMN infiltration and/or
modulating macrophage phenotype through cytokines (e.g., IL-4, IL-13) and/or
lipid mediators (e.g., PD1, RvE3).
as resolvins. RvE1 [5S,12R,18R-trihydroxy-eicosapentaenoic acid
(EPE)] and RvE2 (5S,18R-dihydroxy-EPE) are biosynthesized by
human PMNs via the 5-LOX pathway from a common precursor,
18-hydroxy eicosapentaenoic acid (18-HEPE; Serhan et al., 2000;
Arita et al., 2005; Tjonahen et al., 2006; Oh et al., 2011). Analyses
by unbiased target lipidomics using LC-MS/MS recently showed
that eosinophils converted 18-HEPE into novel 8,18-dihydroxy-
EPE (8,18-diHEPE), 11,18-diHEPE, 12,18-diHEPE, and 17,18-
diHEPE (Isobe et al., 2012). Among those, 17,18-diHEPE, termed
RvE3, displayed potent anti-inflammatory activity by blocking
PMN infiltration in acute peritonitis. Unlike RvE1 and E2, both
of which are biosynthesized by PMNs via the 5-LOX pathway,
RvE3is biosynthesized via the 12/15-LOX pathway, which is highly
expressed in eosinophils (Isobe et al., 2012; Figure 3). As men-
tioned above, eosinophils are recruited to the inflamed loci and
promote resolution of inflammation. Therefore, RvE3 may, at least
in part, contribute to the eosinophils’ function to regulate acute
inflammation and resolution. 12/15-LOX is also expressed in tis-
sue resident macrophages, dendritic cells, mast cells, and airway
epithelial cells (Kühn and O’Donnell, 2006). 12/15-LOX deficiency
leads to progressive atherosclerosis (Merched et al., 2008), exac-
erbation of arthritis, and inflammatory joint destruction (Krönke
et al., 2009), reduced corneal re-epithelialization (Gronert et al.,
2005), and a decline of self tolerance (Uderhardt et al., 2012). Cells
expressing 12/15-LOX might be involved in regulating inflam-
matory responses by locally producing lipid mediators such as
RvE3.
PERSPECTIVES
Eosinophils are known to be involved in allergic diseases
and host protection against parasites through the release of
cytokines/chemokines, mediators, and cytotoxic products. Here
we provide the first evidence that eosinophils act as specific pro-
resolving cells that are recruited and switched on during the
resolution phase of acute peritonitis. Resolution of inflammation
is a highly regulated and coordinated process that involves the
suppression of PMN migration, macrophage recruitment, phago-
cytosis and clearance of apoptotic cells, and tissue debris. In innate
immune responses, the macrophage phenotype is critical in deter-
mining whether the inflamed site resolves or progresses to chronic
inflammation. Resolution phase macrophages express markers
such as mannose receptor (MMR) and CD36, which are typi-
cal of alternatively activated macrophages (Fernandez-Boyanapalli
et al., 2010). A recent study indicates that eosinophils promote
alternative macrophage activation in an IL-4 and IL-13 dependent
manner (Wu et al., 2011). Therefore, it is likely that eosinophils
promote resolution of inflammation by blocking PMN infiltration
and/or modulating macrophage phenotype through cytokines
and/or lipid mediators (Figure 4). Detailed characterization of
eosinophils in the resolution phase will provide insights into the
molecular mechanisms for resolution of inflammation.
Failure of acute inflammation to adequately resolve might
contribute to the development of chronic inflammation and tis-
sue dysfunction. Indeed, some of the most common and diffi-
cult to treat diseases are linked to excessive, uncontrollable, or
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chronic inflammation, including cardiovascular disease, rheuma-
toid arthritis,periodontal disease,asthma,diabetes, and inflamma-
tory bowel disease (IBD), as well as neurological disorders such as
Alzheimer’s disease and age-related macular degeneration (AMD).
The studies summarized here raise the possibility that modulating
eosinophil number and function, or using endogenous mediators
released from eosinophils in the resolution phase could provide
novel therapies for many inflammatory diseases.
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